| |
AS03C
|
AS03C-MPL25
|
AS03C-MPL50
|
AS03B
|
AS03B-MPL25
|
AS03B-MPL50
|
AS03A
|
AS03A-MPL25
|
Non-adjuvanted ≥65 years
|
Non-adjuvanted 18–40 years
|
|---|
| |
N=204
|
N=202
|
N=198
|
N=202
|
N=199
|
N=199
|
N=202
|
N=198
|
N=200
|
N=203
|
|
Age at vaccination (years)
|
|
Mean±SD
|
72.7±5.75
|
72.9±6.09
|
72.6±5.67
|
72.6±5.16
|
72.5±5.66
|
73.0±6.03
|
72.4±5.62
|
72.7±5.56
|
72.7±5.43
|
27.4±6.25
|
|
Median (min–max)
|
72.0
|
71.0
|
72.0
|
72.0
|
72.0
|
72.0
|
71.0
|
72.0
|
72.0
|
27.0
|
|
(63–91)
|
(64–91)
|
(65–94)
|
(65–87)
|
(65–91)
|
(62–95)
|
(65–90)
|
(65–88)
|
(65–89)
|
(18–40)
|
|
Gender, n (%)
|
|
Female
|
95 (46.6)
|
100 (49.5)
|
96 (48.5)
|
109 (54.0)
|
89 (44.7)
|
95 (47.7)
|
105 (52.0)
|
102 (51.5)
|
90 (45.0)
|
103 (50.7)
|
|
Male
|
109 (54.3)
|
102 (50.5)
|
102 (51.5)
|
93 (46.0)
|
110 (55.3)
|
104 (52.3)
|
97 (48.0)
|
96 (48.5)
|
110 (55.0)
|
100 (49.3)
|
|
Geographic Ancestry, n (%)
|
|
African/African American
|
1 (0.5)
|
0
|
2 (1.0)
|
0
|
0
|
1 (0.5)
|
0
|
1 (0.5)
|
0
|
2 (1.0)
|
|
Asian–Central/South
|
1 (0.5)
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
Asian–South East
|
1 (0.5)
|
1 (0.5)
|
2 (1.0)
|
0
|
0
|
1 (0.5)
|
2 (1.0)
|
0
|
0
|
0
|
|
White–Arabic/North African
|
2 (1.0)
|
1 (0.5)
|
1 (0.5)
|
1 (0.5)
|
1 (0.5)
|
1 (0.5)
|
0
|
3 (1.5)
|
0
|
2 (1.0)
|
|
White–Caucasian/European
|
199 (97.5)
|
199 (98.5)
|
193 (97.5)
|
201 (99.5)
|
197 (99.0)
|
195 (98.0)
|
198 (98.0)
|
194 (98.0)
|
200 (100.0)
|
197 (97.0)
|
|
Other
|
0
|
1 (0.5)
|
0
|
0
|
1 (0.5)
|
1 (0.5)
|
2 (1.0)
|
0
|
0
|
2 (1.0)
|
- TVC, total vaccinated cohort; All participants received inactivated trivalent influenza vaccine, non-adjuvanted (≥65 years and 18–40 years) or formulated with an adjuvant. AS03 is a squalene and α-tocopherol oil-in-water emulsion-based Adjuvant System, with tocopherol content 11.86 mg (A), 5.93 mg (B), or 2.97 mg (C); MPL is 3-O-desacyl-4’- monophosphoryl lipid A: 25 μg (MPL-25) or 50 μg (MPL-50).
